Effectiveness and Safety of Intraperitoneal Hyperthermic Perfusion Chemotherapy for Ovarian Cancer: A Systematic Review_Chinese Journal of Evidence-Based Medicine

Authors：

 CHAICheng-liang ,  WANGXiao-hui , CUIYan , SHIXiao-fang

Department of Gynecology and Obstetrics, First Hospital of Lanzhou University, Lanzhou 730000, China;

Corresponding author：

WANGXiao-hui, Email: wxhwxh2006@163.com

Keywords：

Ovarian cancer; Intraperitoneal hyperthermic perfusion chemotherapy; Systematic review; Meta-analysis; Randomized controlled trial

DOI：

10.7507/1672-2531.20140201

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the effectiveness and safety of intraperitoneal hyperthermic perfusion chemotherapy (IHPC) for ovarian cancer, so as to provide references for clinical practice and studies. Methods We electronically searched PubMed, EMbase, The Cochrane Library (Issue 6, 2013), Web of Science, WanFang Data, CBM, VIP and CNKI for randomized controlled trials (RCTs) about IHPC vs. intravenous chemotherapy (IC) for ovarian cancer from the inception of the databases to June 2013. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed methodological quality. Then meta-analysis was performed using RevMan 5.1 software. Results A total of 10 RCTs involving 723 patients were included. The results of meta-analysis showed that the IHPC group was superior to the IC group in clinical efficiency (OR=4.02, 95%CI 2.85 to 5.68, P < 0.000 01), clinical benefit response (OR=3.41, 95%CI 2.13 to 5.45, P < 0.000 01), recurrence and metastasis rates (OR=0.29, 95%CI 0.20 to 0.42, P < 0.000 1), and overall survival rates (OR=3.30, 95%CI 1.82 to 5.99, P < 0.000 1). In the aspect of safety, no significant difference was found in bone marrow suppression, hemoglobin reduction, nausea and vomiting between two groups. Conclusion IHPC for ovarian cancer can improve clinical efficiency, clinical benefit response and overall survival rates, and reduce recurrence and metastasis rates; and it is also safe for patients.

Citation： CHAICheng-liang, WANGXiao-hui, CUIYan, SHIXiao-fang. Effectiveness and Safety of Intraperitoneal Hyperthermic Perfusion Chemotherapy for Ovarian Cancer: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2014, 14(10): 1247-1253. doi: 10.7507/1672-2531.20140201 Copy

1.	Alberts DS, Hannigan EV, Liu P, et al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage Ⅲ ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy:An intergroup study. Gynecologic Oncology, 2006, 100(1):133-138.
2.	章伟玲, 林海英, 张玉泉.腹腔热灌注化疗在卵巢癌治疗中的研究进展.中国妇幼健康研究, 2008, 19(5):491-494.
3.	Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011]. The Cochrane Collaboration, 2011. Available at:www.cochrane-handbook.org.
4.	周建炜, 吕银祥, 王秋红, 等.腹腔热灌注联合化疗在卵巢浆液性囊腺癌初次术后中的应用探索.实用肿瘤杂志, 2010, 25(3):351-354.
5.	冯燕, 翟红岩, 查斌斌, 等. 35例卵巢癌术后腹腔热灌注化疗临床疗效观察.社区医学杂志, 2009, 7(21):19-20.
6.	胡宗兰, 曹军丽, 顾涛, 等.腹腔热灌注化疗联合全身化疗在卵巢癌恶性腹腔积液控制中的近期疗效.山东医药, 2009, 49(40):42-43.
7.	任春振, 曹军丽, 胡宗兰, 等.腹腔热灌注化疗联合静脉化疗治疗晚期卵巢癌的临床观察.中国肿瘤临床, 2010, 37(24):1459-1461.
8.	吴素芳, 谢优优, 陈佩芳.重组人血管内皮抑制素联合静脉化疗和腹腔热灌注化疗治疗晚期卵巢癌的临床研究.中国医师进修杂志, 2013, 36(3):10-13.
9.	李小瑞, 杨军, 孙蔚亮, 等.腹腔灌注及静脉化疗配合热疗治疗晚期卵巢癌的临床观察.医学信息内·外科版, 2009, 22(2):131-132.
10.	梁冰, 杨家梅, 贺新伟.全身化疗联合腹腔热灌注化疗并射频热疗治疗晚期卵巢癌.医药论坛杂志, 2009, 30(24):57-58.
11.	陈红娜, 王海增.腹腔持续热化疗治疗卵巢癌腹水的疗效与Ca125的相关性研究.中国医药导报, 2009, 11(6):903-904.
12.	王秀清, 方献英, 柏峰.晚期卵巢癌术后早期顺铂腹腔热灌注化疗临床研究.现代肿瘤医学, 2011, 19(10):2061-2063.
13.	梁云芳.双化疗途径治疗卵巢癌的临床疗效分析.中国医师杂志, 2011, 02(z2):82-83.
14.	Vasey PA, Herrstedt J, Jelic S. ESMO Guidelines Task Force:ESMO minimum clinical recommendations for diagonosis, treatment and follow-up of epithelial ovarian carcinoma. Ann Oncol, 2005, 16(suppl 1):i13-i15.
15.	Sugarbaker PH. Peritoneal cardnomatosis:natural history and rational therapeutic interventions using intraperitoneal chemotherapy. Cancer Treat Res, 1996, 81(2):149-168.
16.	Zanon C, Clara R, Chiappino I, et al. Cytoreductive surgery and intraperitoneal chemohyperthexmia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg, 2004, 28(10):1040-1045.
17.	Lentz SS, Miller BE, Kucera GLK, et al. Intraperitoneal hypertherrmic chemotherapy using carboplatin:A phase I analysis in ovarian carcinoma. Gynecol Oncol, 2007, 106(1):207-210.
18.	罗奋, 沈敏, 蔡端.腹腔温热化疗研究现状和进展.国外医学肿瘤学分册, 2001, 28(2):152-153.
19.	Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy:Current status and future directions. Arm Sttrg Oncol, 2005, 12(10):765-777.
20.	Glehen O, Kwintkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal Cancer:a multi-institutional study. J Clin Oncol, 2004, 22(16):3284-3292.

1. Alberts DS, Hannigan EV, Liu P, et al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage Ⅲ ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy:An intergroup study. Gynecologic Oncology, 2006, 100(1):133-138.
2. 章伟玲, 林海英, 张玉泉.腹腔热灌注化疗在卵巢癌治疗中的研究进展.中国妇幼健康研究, 2008, 19(5):491-494.
3. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011]. The Cochrane Collaboration, 2011. Available at:www.cochrane-handbook.org.
4. 周建炜, 吕银祥, 王秋红, 等.腹腔热灌注联合化疗在卵巢浆液性囊腺癌初次术后中的应用探索.实用肿瘤杂志, 2010, 25(3):351-354.
5. 冯燕, 翟红岩, 查斌斌, 等. 35例卵巢癌术后腹腔热灌注化疗临床疗效观察.社区医学杂志, 2009, 7(21):19-20.
6. 胡宗兰, 曹军丽, 顾涛, 等.腹腔热灌注化疗联合全身化疗在卵巢癌恶性腹腔积液控制中的近期疗效.山东医药, 2009, 49(40):42-43.
7. 任春振, 曹军丽, 胡宗兰, 等.腹腔热灌注化疗联合静脉化疗治疗晚期卵巢癌的临床观察.中国肿瘤临床, 2010, 37(24):1459-1461.
8. 吴素芳, 谢优优, 陈佩芳.重组人血管内皮抑制素联合静脉化疗和腹腔热灌注化疗治疗晚期卵巢癌的临床研究.中国医师进修杂志, 2013, 36(3):10-13.
9. 李小瑞, 杨军, 孙蔚亮, 等.腹腔灌注及静脉化疗配合热疗治疗晚期卵巢癌的临床观察.医学信息内·外科版, 2009, 22(2):131-132.
10. 梁冰, 杨家梅, 贺新伟.全身化疗联合腹腔热灌注化疗并射频热疗治疗晚期卵巢癌.医药论坛杂志, 2009, 30(24):57-58.
11. 陈红娜, 王海增.腹腔持续热化疗治疗卵巢癌腹水的疗效与Ca125的相关性研究.中国医药导报, 2009, 11(6):903-904.
12. 王秀清, 方献英, 柏峰.晚期卵巢癌术后早期顺铂腹腔热灌注化疗临床研究.现代肿瘤医学, 2011, 19(10):2061-2063.
13. 梁云芳.双化疗途径治疗卵巢癌的临床疗效分析.中国医师杂志, 2011, 02(z2):82-83.
14. Vasey PA, Herrstedt J, Jelic S. ESMO Guidelines Task Force:ESMO minimum clinical recommendations for diagonosis, treatment and follow-up of epithelial ovarian carcinoma. Ann Oncol, 2005, 16(suppl 1):i13-i15.
15. Sugarbaker PH. Peritoneal cardnomatosis:natural history and rational therapeutic interventions using intraperitoneal chemotherapy. Cancer Treat Res, 1996, 81(2):149-168.
16. Zanon C, Clara R, Chiappino I, et al. Cytoreductive surgery and intraperitoneal chemohyperthexmia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg, 2004, 28(10):1040-1045.
17. Lentz SS, Miller BE, Kucera GLK, et al. Intraperitoneal hypertherrmic chemotherapy using carboplatin:A phase I analysis in ovarian carcinoma. Gynecol Oncol, 2007, 106(1):207-210.
18. 罗奋, 沈敏, 蔡端.腹腔温热化疗研究现状和进展.国外医学肿瘤学分册, 2001, 28(2):152-153.
19. Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy:Current status and future directions. Arm Sttrg Oncol, 2005, 12(10):765-777.
20. Glehen O, Kwintkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal Cancer:a multi-institutional study. J Clin Oncol, 2004, 22(16):3284-3292.

Previous Article
Combination of Entecavir and IFN-α for Chronic Hepatitis B: A Systematic Review
Next Article
Chinese Herbal Enema plus Gastrointestinal Intubation for Ileus: A Systematic Review

Chinese Journal of Evidence-Based Medicine

Effectiveness and Safety of Intraperitoneal Hyperthermic Perfusion Chemotherapy for Ovarian Cancer: A Systematic Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content